Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Infertility: HELP
Articles by Nathalie Chabbert-Buffet
Based on 16 articles published since 2009
(Why 16 articles?)
||||

Between 2009 and 2019, N. Chabbert-Buffet wrote the following 16 articles about Infertility.
 
+ Citations + Abstracts
1 Guideline [Management of endometriosis: CNGOF-HAS practice guidelines (short version)]. 2018

Collinet, P / Fritel, X / Revel-Delhom, C / Ballester, M / Bolze, P A / Borghese, B / Bornsztein, N / Boujenah, J / Bourdel, N / Brillac, T / Chabbert-Buffet, N / Chauffour, C / Clary, N / Cohen, J / Decanter, C / Denouël, A / Dubernard, G / Fauconnier, A / Fernandez, H / Gauthier, T / Golfier, F / Huchon, C / Legendre, G / Loriau, J / Mathieu-d'Argent, E / Merlot, B / Niro, J / Panel, P / Paparel, P / Philip, C A / Ploteau, S / Poncelet, C / Rabischong, B / Roman, H / Rubod, C / Santulli, P / Sauvan, M / Thomassin-Naggara, I / Torre, A / Wattier, J M / Yazbeck, C / Canis, M. ·Clinique de gynécologie, hôpital Jeanne-de-Flandre, CHRU de Lille, 59000 Lille, France; Université Lille-Nord-de-France, 59000 Lille, France. Electronic address: pierre.collinet@chru-lille.fr. · Service de gynécologie-obstétrique et médecine de la reproduction, Inserm CIC 1402, 2, rue de la Milétrie, 86000 Poitiers, France; Université de Poitiers, 86000 Poitiers, France; Inserm CIC 1402, 86000 Poitiers, France. · Haute Autorité de santé, 5, avenue du Stade-de-France, 93218 La Plaine-Saint-Denis cedex, France. · Service de gynécologie-obstétrique et médecine de la reproduction, CHU Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France. · Service de chirurgie gynécologique oncologique, obstétrique, CHU Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université Claude-Bernard-Lyon 1, 69000 Lyon, France. · Service de chirurgie gynécologie-obstétrique 2 et médecine de la reproduction, CHU Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Équipe génomique, épigénétique et physiopathologie de la reproduction, département développement, reproduction, cancer, Inserm U1016, université Paris Descartes, Sorbonne Paris Cité, 12, rue de l'École-de-Médecine, 75270 Paris cedex 06, France. · 29, rue de l'Essonne, 91000 Evry, France. · Service de gynécologie-obstétrique, CHU Bondy, avenue du 14-Juillet, 93140 Bondy, France; Centre médical du Château, 22, rue Louis-Besquel, 94300 Vincennes, France. · Service de gynécologie-obstétrique et reproduction humaine, CHU Estaing, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France; Faculté de médecine, Encov-ISIT, UMR6284 CNRS, université d'Auvergne, 28, place Henri-Dunant, 63000 Clermont-Ferrand, France. · 98, route de Blagnac, 31200 Toulouse, France. · Service de gynécologie-obstétrique et médecine de la reproduction, CHU Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; GRC-6 centre expert en endométriose (C3E), Sorbonne université, Paris, France; UMR-S938 Inserm Sorbonne université, Paris, France. · Service de gynécologie-obstétrique et reproduction humaine, CHU Estaing, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France. · 3, rue Pablo-Picasso, 92160 Antony, France. · Service d'assistance médicale à la procréation et de préservation de la fertilité, hôpital Jeanne-de-Flandre, CHRU de Lille, 1, rue Eugène-Avinée, 59037 Lille cedex, France; EA 4308 gamétogenèse et qualité du gamète, CHRU de Lille, 59037 Lille cedex, France. · EndoFrance, BP 50053, 01124 Montluel cedex, France. · Université Claude-Bernard-Lyon 1, 69000 Lyon, France; Clinique gynécologique et obstétricale, hôpital de la Croix-Rousse, groupe hospitalier Nord, CHU de Lyon-HCL, 103, grande rue de la Croix-Rousse, 69317 Lyon cedex, France. · Service de gynécologie-obstétrique, CHI Poissy-St-Germain, 10, rue du Champ-Gaillard, 78303 Poissy, France; EA 7285 risques cliniques et sécurité en santé des femmes, université Versailles-Saint-Quentin-en-Yvelines, Saint-Quentin-en-Yvelines, France. · Service de gynécologie-obstétrique, CHU Bicêtre, AP-HP, 78, avenue du Général-de-Gaulle, 94275 Le Kremlin-Bicêtre, France; CESP-INSERM, U1018, équipe épidémiologie et évaluation des stratégies de prise en charge, VIH, reproduction, pédiatrie, université Paris-Sud, Paris, France. · Service de gynécologie-obstétrique, hôpital Mère-Enfant, CHU de Limoges, 8, avenue Dominique-Larrey, 87042 Limoges, France; UMR-1248, faculté de médecine, 87042 Limoges, France. · Service de chirurgie gynécologique oncologique, obstétrique, CHU Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France. · Service de gynécologie-obstétrique, CHI Poissy-St-Germain, 10, rue du Champ-Gaillard, 78303 Poissy, France. · Service de gynécologie-obstétrique, CHU d'Angers, 4, rue Larrey, 49033 Angers cedex 01, France; CESP-Inserm, U1018, équipe 7, genre, santé sexuelle et reproductive, université Paris-Sud, 94276 Le Kremlin-Bicêtre cedex, France. · Service de chirurgie digestive, groupe hospitalier Paris Saint-Joseph, 185, rue Raymond-Losserand, 75001 Paris, France. · Service de gynécologie-obstétrique et médecine de la reproduction, CHU Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Université Pierre-et-Marie-Curie Paris 6, Paris, France; GRC6-UPMC, centre expert en endométriose (C3E), hôpital Tenon, Paris, France. · Service de chirurgie gynécologique, clinique Tivoli, 220, rue Mandron, 33000 Bordeaux, France. · Service de gynécologie-obstétrique, centre hospitalier de Versailles, 177, route de Versailles, 78157 Le Chesnay cedex, France. · Service d'urologie, CHU Lyon-Sud, 165, chemin du Grand-Revoyet, 60495 Pierre-Bénite, France. · Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Mère-Enfant, CHU de Nantes, 8, boulevard Jean-Monnet, 44093 Nantes, France. · Service de gynécologie-obstétrique, centre hospitalier Renée-Dubos, 6, avenue de l'Île-de-France, 95300 Pontoise, France; Université Paris 13, Sorbonne Paris Cité, UFR SMBH, 93022 Bobigny, France. · Centre expert de diagnostic et prise en charge multidisciplinaire de l'endométriose, clinique gynécologique et obstétricale, CHU Charles-Nicolle, 1, rue de Germont, 76031 Rouen, France. · Clinique de gynécologie, hôpital Jeanne-de-Flandre, CHRU de Lille, 59000 Lille, France; Université Lille-Nord-de-France, 59000 Lille, France. · Service de gynécologie-obstétrique, CHU Bicêtre, AP-HP, 78, avenue du Général-de-Gaulle, 94275 Le Kremlin-Bicêtre, France. · Service d'imagerie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Sorbonne universités, UPMC université Paris 06, Paris, France; Institut universitaire de cancérologie, Assistance publique, Paris, France. · Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier, France. · Centre d'étude et traitement de la douleur, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonowski, 59000 Lille, France. · Service de gynécologie-obstétrique, hôpital Foch, AP-HP, 40, rue Worth, 92151 Suresnes, France; Centre d'assistance médicale à la procréation, clinique Pierre-Cherest, 5, rue Pierre-Cherest, 92200 Neuilly-Sur-Seine, France. ·Gynecol Obstet Fertil Senol · Pubmed #29550339.

ABSTRACT: First-line investigations to diagnose endometriosis are clinical examination and pelvic ultrasound. Second-line investigations include pelvic examination performed by a referent clinician, transvaginal ultrasound performed by a referent echographist, and pelvic MRI. It is recommended to treat endometriosis when it is symptomatic. First-line hormonal treatments recommended for the management of painful endometriosis are combined with hormonal contraceptives or levonorgestrel 52mg IUD. There is no evidence to recommend systematic preoperative hormonal therapy for the unique purpose of preventing the risk of surgical complications or facilitating surgery. After endometriosis surgery, combined hormonal contraceptives or levonorgestrel SIU 52mg are recommended as first-line therapy in the absence of desire of pregnancy. In case of initial treatment failure, recurrence, or multiple organ involvement by endometriosis, medico-surgical and multidisciplinary discussion is recommended. The laparoscopic approach is recommended for the surgical treatment of endometriosis. HRT may be offered in postmenopausal women operated for endometriosis. In case of infertility related to endometriosis, it is not recommended to prescribe anti-gonadotropic hormone therapy to increase the rate of spontaneous pregnancy, including postoperatively. The possibilities of fertility preservation should be discussed with the patient in case of surgery for ovarian endometrioma.

2 Guideline [New medical treatments for painful endometriosis: CNGOF-HAS Endometriosis Guidelines]. 2018

Legendre, G / Delbos, L / Hudon, E / Chabbert-Buffet, N / Geoffron, S / Sauvan, M / Fernandez, H / Bouet, P-E / Descamps, P. ·Service de gynécologie-obstétrique, CHU Angers, 4, rue Larrey, 49033 Angers cedex 01, France; CESP-Inserm, U1018, équipe 7, genre, santé sexuelle et reproductive, UVSQ, université Paris-Saclay, université Paris Sud, 94807 Villejuif, France. Electronic address: guillaume.legendre@chu-angers.fr. · Service de gynécologie-obstétrique, CHU Angers, 4, rue Larrey, 49033 Angers cedex 01, France. · Service de gynécologie-obstétrique et médecine de la reproduction, Sorbonne université, centre de recherche Saint-Antoine, GRC-6 centre expert en endométriose (CE3), Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Est parisien-Tenon, 75020 Paris, France. · Service de gynécologie-obstétrique, Assistance publique-Hôpitaux de Paris, hôpital de Bicêtre, 94276 Le Kremlin Bicêtre cedex, France. ·Gynecol Obstet Fertil Senol · Pubmed #29530558.

ABSTRACT: OBJECTIVE: The objective of this work is to evaluate the place of new treatments in the management of endometriosis outside the context of infertility. METHODS: A review of the literature was conducted by consulting Medline data until July 2017. RESULTS: Dienogest is effective compared to placebo in short term (NP2) and long term (NP4) for the treatment of painful endometriosis. In comparison with GnRH agonists, dienogest is also effective in terms of decreased pain and improved quality of life in non-operated patients (NP2) as well as for recurrence of lesions and symptomatology postoperatively (NP2). Data on GnRH antagonists, selective progesterone receptor modulators as well as selective inhibitors (anti-TNF-α, matrix metalloprotease inhibitors, angiogenesis growth factor inhibitors) are insufficient to provide evidence of interest in clinical practice for the management of painful endometriosis (NP3). CONCLUSION: Dienogest is recommended as second-line therapy for the management of painful endometriosis (Grade B). Because of lack of evidence, aromatase inhibitors, elagolix, SERM, SPRM and anti-TNF-α are not recommended for the management of painful endometriosis (Grade C).

3 Guideline [Medical treatment for the management of painful endometriosis without infertility: CNGOF-HAS Endometriosis Guidelines]. 2018

Sauvan, M / Chabbert-Buffet, N / Canis, M / Collinet, P / Fritel, X / Geoffron, S / Legendre, G / Wattier, J-M / Fernandez, H. ·Service de gynécologie-obstétrique, CHU Bicêtre, AP-HP, 78, avenue du Général de Gaulle, 94275 Le Kremlin-Bicêtre, France. Electronic address: marine.sauvan@aphp.fr. · Service de gynécologie-obstétrique et médecine de la reproduction, CHU Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; GRC-6 centre expert en endométriose (C3E), Sorbonne université, 75005 Paris, France; UMR-S938 inserm Sorbonne université, 75005 Paris, France. · Service de gynécologie-obstétrique et reproduction humaine, CHU Estaing, 1, place Lucie Aubrac, 63003 Clermont-Ferrand, France; Faculté de médecine, Encov-ISIT, UMR6284 CNRS, université d'Auvergne, 28, place Henri Dunant, 63000 Clermont-Ferrand, France. · Clinique de gynécologie, hôpital Jeanne-de-Flandre, CHRU Lille, 59000 Lille, France; Université Lille-Nord-de-France, 59000 Lille, France. · Service de gynécologie-obstétrique et médecine de la reproduction, inserm CIC 1402, 2, rue de la Milétrie, 86000 Poitiers, France; Université de Poitiers, 86000 Poitiers, France; Inserm CIC 1402, 86000 Poitiers, France. · Service de gynécologie-obstétrique et médecine de la reproduction, CHU Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France. · Service de gynécologie-obstétrique, CHU Angers, 4, rue Larrey, 49033 Angers cedex 01, France; CESP-inserm, U1018, équipe 7, genre, santé sexuelle et reproductive, université Paris Sud, 94276 Le Kremlin-Bicêtre cedex, France. · Centre d'étude et traitement de la douleur, hôpital Claude Huriez, CHRU Lille, rue Michel Polonowski, 59000 Lille, France. · Service de gynécologie-obstétrique, CHU Bicêtre, AP-HP, 78, avenue du Général de Gaulle, 94275 Le Kremlin-Bicêtre, France; CESP-inserm, U1018, équipe épidémiologie et évaluation des stratégies de prise en charge : VIH, reproduction, pédiatrie, université Paris Sud, 94270 Le Kremlin-Bicêtre, France. ·Gynecol Obstet Fertil Senol · Pubmed #29510966.

ABSTRACT: OBJECTIVE: To provide clinical practice guidelines for the management of painful endometriosis in women without infertility. METHODS: Systematic review of the literature literature since 2006, level of evidence rating, external proofreading and grading of the recommendation grade by an expert group according to HAS methodology. RESULTS: Combined hormonal contraceptives (COP) and the levonorgestrel-releasing intra-uterin system (LNG-IUS) are recommended as first-line hormonal therapies for the treatment of painful endometriosis (grade B). Second-line therapy relies on oral desogestrel microprogestative, etonogestrel-releasing implant, GnRH analogs (GnRHa) and dienogest (grade C). It is recommended to use add-back therapy containing estrogen in association with GnRHa (grade B). After endometriosis surgery, hormonal treatment relying on COP or LNG-IUS is recommended to prevent pain recurrence (grade B). COP is recommended to reduce the risk of endometrioma recurrence after surgery (grade B) but the prescription of GnRHa is not recommended (grade C). Continuous COP is recommended in case of dysmenorrhea (grade B). GnRHa is not recommended as first line endometriosis treatment for adolescent girl because of the risk of bone demineralization (grade B). The management of endometriosis-induced chronic pain requires an interdisciplinary evaluation. Physical therapies improving the quality of life such as yoga, relaxation or osteopathy can be proposed (expert agreement). Promising medical alternatives are currently under preclinical and clinical evaluation.

4 Guideline [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]. 2018

Rousset-Jablonski, Christine / Selle, Fréderic / Adda-Herzog, Elodie / Planchamp, François / Selleret, Lise / Pomel, Christophe / Chabbert-Buffet, Nathalie / Daraï, Emile / Pautier, Patricia / Trémollières, Florence / Guyon, Frederic / Rouzier, Roman / Laurence, Valérie / Chopin, Nicolas / Faure-Conter, Cécile / Bentivegna, Enrica / Vacher-Lavenu, Marie-Cécile / Lhomme, Catherine / Floquet, Anne / Treilleux, Isabelle / Lecuru, Fabrice / Gouy, Sébastien / Kalbacher, Elsa / Genestie, Catherine / de la Motte Rouge, Thibault / Ferron, Gwenael / Devouassoux-Shisheboran, Mojgan / Kurtz, Jean-Emmanuel / Namer, Moise / Joly, Florence / Pujade-Lauraine, Eric / Grynberg, Michael / Querleu, Denis / Morice, Philippe / Gompel, Anne / Ray-Coquard, Isabelle. ·Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. Electronic address: christine.rousset-jablonski@lyon.unicancer.fr. · Groupe hospitalier Diaconesses Croix-Saint-Simon, 12-18, rue du Sergent-Bauchat, 75012 Paris, France. · Hôpital Foch, service de gynécologie-obstétrique, 40, rue Worth, 92151 Suresnes, France. · Institut Bergonié, 229, Cours-de-l'Argonne, 33000 Bordeaux, France. · Hôpital Tenon, service de gynécologie-obstétrique et médecine de la reproduction, 4, rue de la Chine, 75020 Paris, France. · Centre Jean-Perrin, 58, rue Montalembert BP, 392, 63011 Clermont-Ferrand cedex 1, France. · Institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94800 Villejuif, France. · Hôpital Paule-de-Viguier, centre de ménopause et de dépistage de l'ostéoporose, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France. · Institut Curie, 26, rue d'Ulm, 75005 Paris, France. · Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France. · Hôpital Cochin-Port Royal, 53, avenue de l'Observatoire, 75014 Paris, France. · Hôpital Européen Geroges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · CHU Besançon-Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France. · Centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France. · CLCC, institut Claudius-Regaud, IUCT Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. · Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. · CHU de Strasbourg, hôpital de Hautepierre, avenue Molière, 67200 Strasbourg, France. · Recommandations pour la pratique clinique, Nice-Saint-Paul, 06000 Nice, France. · Centre François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France. · CHU Paris Centre, hôpital Hôtel-Dieu, 1, place du Parvis-Notre-Dame, 75004 Paris, France. · Hôpital Jean-Verdier, avenue du 14 juillet, 93140 Bondy, France. ·Bull Cancer · Pubmed #29397916.

ABSTRACT: INTRODUCTION: Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. METHODS: A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. RESULTS: Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. DISCUSSION: In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.

5 Editorial [How to improve endometriosis management]. 2017

Daraï, Emile / Chabbert-Buffet, Nathalie. ·AP-HP, université Pierre-et-Marie-Curie Paris 6, hôpital Tenon, service de gynécologie-obstétrique et reproduction humaine, 4, rue de la Chine, 75020 Paris, France; Centre expert en endométriose (C3E), Groupe de recherche clinique (GRC-6 UPMC), inserm UMRS-938, France. ·Presse Med · Pubmed #29224704.

ABSTRACT: -- No abstract --

6 Review Finding the balance between surgery and medically-assisted reproduction in women with deep infiltrating endometriosis. 2016

Cohen, Jonathan / Ballester, Marcos / Selleret, Lise / Mathieu D'Argent, Emmanuelle / Antoine, Jean M / Chabbert-Buffet, Nathalie / Darai, Emile. ·Department of Gynecology, Obstetrics and Reproductive Medicine, Tenon Hospital, Assistance Publique des Hôpitaux de Paris, Pierre et Marie Curie Paris 6 University, GRC6-UPMC - Specialized Center for Endometriosis (C3E), Paris, France - drcohenjonathan@gmail.com. ·Minerva Ginecol · Pubmed #27098393.

ABSTRACT: Deep infiltrating endometriosis (DIE) affects several anatomical locations including the bladder, torus uterinum, uterosacral ligament, rectovaginal septum and bowel. It is the most debilitating form of endometriosis and causes severe pain, digestive and urinary symptoms as well as infertility. Faced with an infertile woman suffering from DIE, the dilemma is whether to opt for first-line IVF treatment or for surgery. In the absence of high-level of evidence from randomized studies, several factors should be taken into account in the decision-making process. The main criterion is whether the patient wants in-vitro fertilization (IVF) treatment or not. Secondly, while previous reports have demonstrated the positive impact of surgery on pregnancy, they also underline the risk of severe complications requiring management in expert centers. Despite the availability of predictive models or scoring systems, the decision mainly boils down to the couple's characteristics. It seems logical to propose first-line IVF when spontaneous fertility is not possible due to associated male infertility or tubal obstruction; for women aged ≥35 years; or in women with diminished ovarian reserve. Conversely, first-line surgery could be the best option for women without these characteristics. However, this strategy is mainly based on low-level of evidence underlining the requiring of randomized trials.

7 Review [Role of GnRH agonists in preserving female fertility]. 2014

Thomin, A / Torre, A / Daraï, É / Chabbert-Buffet, N. ·Service de gynécologie obstétrique, médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France. Electronic address: anne.thomin@tnn.aphp.fr. · Service de gynécologie obstétrique, médecine de la reproduction, centre hospitalier intercommunal Poissy, 78300 Saint-Germain-en-Laye, France. · Service de gynécologie obstétrique, médecine de la reproduction, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France. ·J Gynecol Obstet Biol Reprod (Paris) · Pubmed #24321862.

ABSTRACT: The impact of cancer treatment on ovarian function and fertility has been known since the 70s. Preservation of fertility is now an important focus of care for patients of reproductive age with cancer. The beneficial role of GnRH agonists in fertility preservation is controversial since the early 2000s. Recent randomized studies come to overturn this role. The POEMS multicenter randomized trial with long-term follow-up is ongoing and will provide results that could help clarify the current uncertain indication of these compounds in this context.

8 Review Pregnancy after breast cancer: a need for global patient care, starting before adjuvant therapy. 2010

Chabbert-Buffet, Nathalie / Uzan, Catherine / Gligorov, Joseph / Delaloge, Suzette / Rouzier, Roman / Uzan, Serge. ·APHP, Hôpital Tenon, Département de Gynécologie-Obstétrique et Médecine de la Reproduction, 4 rue de la Chine - 75571 Paris Cedex 20, France. nathalie.chabbert-buffet@tnn.aphp.fr ·Surg Oncol · Pubmed #19443211.

ABSTRACT: Breast cancer (BC) is the most frequently occurring cancer in women; early diagnosis and efficient treatments create higher event-free and overall survival rates. However, the mean age at first pregnancy continues to increase worldwide; the question of pregnancy after BC is thus raised more frequently. Chemotherapy may induce premature ovarian failure, depending largely on the woman's age and the drugs used, as well as the dosage and duration of treatment. It is important that fertility preservation strategies are addressed before chemotherapy. Pregnancy after BC may implicate a potentially higher risk of cancer recurrence, but the available literature provides reassuring data. The delay between cancer treatment and pregnancy should be discussed, depending on the initial stage of the disease. The risk of discontinuing tamoxifen prematurely should be carefully evaluated using standardised tools. The pregnancy outcome may as well be impaired by the history of cancer, leading to an increased likelihood of preterm birth and low birth weight rates. Proper follow-up and prevention should be provided based on the knowledge of these complications. Pregnancy after BC should be possible for most young BC patients in the future. This implies a global care program including multi-disciplinary teams is initiated prior to starting adjuvant treatment and particularly chemotherapy. The patient and her partner should be involved in the various steps of the process, after being properly informed.

9 Article Benign polypoid adenomyomatous endometrium associated with hpt-JT syndrome: a case report. 2019

Arfi, Alexandra / Chabbert-Buffet, Nathalie / Boudy, Anne-Sophie / de Foucher, Tiphaine / Owen, Clémentine / Bendifallah, Sofiane / Darai, Emile. ·Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique Des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie , Paris , France. · Centre de recherche Saint Antoine (UMRS 938), Faculté de Médecine Sorbonne Université , Paris , France. · INSERM UMR_S_707, 'Epidemiology, Information Systems, Modeling', University Pierre and Marie Curie , Paris , France. · Centre Expert En Endométriose (C3E), Assistance publique des hôpitaux de Paris, hôpital Tenon, service de gynécologie-obstétrique et reproduction humaine, Paris, France. ·Gynecol Endocrinol · Pubmed #31429335.

ABSTRACT: Hyperparathyroidism-jaw tumor (HPT-JT) is an autosomal dominant disorder responsible for benign and/or malignant tumors. Affected women often present life-threatening menorrhagia that leads to the identification of uterine tumors, and experience miscarriages and infertility. Overall though, fewer data concerning gynecological pathologies related to HPT-JT syndrome are available. We report the case of a 32-year-old woman with HPT-JT syndrome, referred for recurrent vaginal bleeding, with a history of repeated endometrial polyps and infertility. We also review the literature that explores medical options for these women.

10 Article Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. 2019

Rousset-Jablonski, Christine / Selle, Fréderic / Adda-Herzog, Elodie / Planchamp, François / Selleret, Lise / Pomel, Christophe / Daraï, Emile / Chabbert-Buffet, Nathalie / Pautier, Patricia / Trémollières, Florence / Guyon, Frederic / Rouzier, Roman / Laurence, Valérie / Chopin, Nicolas / Faure-Conter, Cécile / Bentivegna, Enrica / Vacher-Lavenu, Marie-Cécile / Lhomme, Catherine / Floquet, Anne / Treilleux, Isabelle / Lecuru, Fabrice / Gouy, Sébastien / Kalbacher, Elsa / Genestie, Catherine / Thibault, de la Motte Rouge / Ferron, Gwenael / Devouassoux, Mojgan / Kurtz, Jean-Emmanuel / Provansal, Magali / Namer, Moise / Joly, Florence / Pujade-Lauraine, Eric / Grynberg, Michael / Querleu, Denis / Morice, Philippe / Gompel, Anne / Ray-Coquard, Isabelle. ·Leon Berard Cancer Center, 28 Rue Laënnec, 69008, Lyon, France; Université Claude Bernard Lyon 1, EA 7425 Hesper, Health Service and Performance Research, Domaine Rockefeller, 8 Avenue Rockefeller, 69373, Lyon Cedex 8, France. Electronic address: christine.rousset-jablonski@lyon.unicancer.fr. · Groupe Hospitalier Diaconesses Croix Saint Simon, 12-18 Rue Du Sergent Bauchat, 75012, Paris, France. · Hôpital Foch, Service de Gynécologie-Obstétrique, 40 Rue Worth, 92151, Suresnes, France. · Bergonié Institute Cancer Center, 229 Cours de L'Argonne, 33000, Bordeaux, France. · Hôpital Tenon, Service de Gynécologie-Obstétrique et Médecine de La Reproduction, 4 Rue de La Chine, 75020, Paris, France. · Jean Perrin Cancer Center, 58 Rue Montalembert BP 392, 63011, Clermont-Ferrand Cedex 1, France. · Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94800, Villejuif, France. · Hôpital Paule de Viguier, Centre de Ménopause et de Dépistage de L'Ostéoporose 330, Avenue de Grande-Bretagne, TSA 70034, 31059, Toulouse Cedex 9, France. · Curie Institute Cancer Center, 26 Rue D'Ulm, 75005, Paris, France. · Leon Berard Cancer Center, 28 Rue Laënnec, 69008, Lyon, France. · Hôpital Cochin-Port Royal, 53 Avenue de L'Observatoire, 75014, Paris, France. · Hôpital Européen Geroges Pompidou, 20 Rue Leblanc, 75015, Paris, France. · CHU Besançon Jean Minjoz, 3 Bd Alexandre Fleming, 25030, Besancon, cedex, France. · Eugene Marquis Cancer Center, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France. · Claudius Regaud Cancer Center, IUCT Oncopole, 1 Av. Irène Joliot-Curie, 31100, Toulouse, France. · Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 165, Chemin Du Grand Revoyet, 69495, Pierre-Bénite Cedex, France. · CHU de Strasbourg, Hôpital de Hautepierre, Avenue Molière, 67200, Strasbourg, France. · Paoli-Calmette Institute, 232 Sainte-Marguerite Boulevard, 13009, Marseille, France. · Recommandations pour La Pratique Clinique, Nice-Saint-Paul, 06000, France. · François Baclesse Cancer Center, 3 Avenue Du Général Harris, 14076, Caen Cedex 5, France. · CHU Paris Centre - Hôpital Hôtel-Dieu, 1 Place Du Parvis Notre-Dame, 75004, Paris, France. · Hôpital Jean Verdier, Avenue Du 14 Juillet, 93140, Bondy, France. · Université Paris-Descartes, 12 Rue de L'école de Médecine, 75006, Paris, France. · Leon Berard Cancer Center, 28 Rue Laënnec, 69008, Lyon, France; Université Claude Bernard Lyon 1, EA 7425 Hesper, Health Service and Performance Research, Domaine Rockefeller, 8 Avenue Rockefeller, 69373, Lyon Cedex 8, France; Groupe GINECO, France. ·Eur J Cancer · Pubmed #31170563.

ABSTRACT: INTRODUCTION: Rare ovarian tumours include complex borderline ovarian tumours, sex-cord tumours, germ cell tumours and rare epithelial tumours. Indications and modalities of fertility preservation (FP), infertility management, contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and experts in reproductive medicine and gynaecology have built guidelines on FP, contraception and menopause hormone therapy in women treated for ovarian rare tumours. MATERIAL AND METHODS: A panel of 35 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review and then rated through two successive rounds. RESULTS: Thirty-five recommendations were identified, concerning indications for FP, contraindications for ovarian stimulation, contraceptive options and menopause hormone therapy for each tumour type. DISCUSSION: Overall, caution has been recommended in the case of potentially hormone-sensitive tumours such as sex-cord tumours, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumours. CONCLUSION: In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.

11 Article Management of endometriosis: CNGOF/HAS clinical practice guidelines - Short version. 2018

Collinet, P / Fritel, X / Revel-Delhom, C / Ballester, M / Bolze, P A / Borghese, B / Bornsztein, N / Boujenah, J / Brillac, T / Chabbert-Buffet, N / Chauffour, C / Clary, N / Cohen, J / Decanter, C / Denouël, A / Dubernard, G / Fauconnier, A / Fernandez, H / Gauthier, T / Golfier, F / Huchon, C / Legendre, G / Loriau, J / Mathieu-d'Argent, E / Merlot, B / Niro, J / Panel, P / Paparel, P / Philip, C A / Ploteau, S / Poncelet, C / Rabischong, B / Roman, H / Rubod, C / Santulli, P / Sauvan, M / Thomassin-Naggara, I / Torre, A / Wattier, J M / Yazbeck, C / Bourdel, N / Canis, M. ·CHRU Lille, Clinique de gynécologie, Hôpital Jeanne de Flandre, 59000 Lille, France; Université Lille-Nord-de-France, 59000 Lille, France. · Service de Gynécologie-Obstétrique et Médecine de la reproduction, Inserm CIC 1402, 2, rue de la Milétrie, 86000 Poitiers, France; Université de Poitiers, 86000 Poitiers, France; Inserm CIC 1402, 86000 Poitiers, France. · Haute Autorité de Santé, 5 avenue du Stade de France, 93218 La Plaine St Denis Cedex, France. · Service de Gynécologie-Obstétrique et Médecine de la reproduction, CHU Tenon, APHP, 4, rue de la Chine, 75020 Paris, France. · Service de Chirurgie Gynécologique Oncologique, Obstétrique, CHU Lyon Sud, 165, chemin du Grand Revoyet, 69495 Pierre Bénite, France; Université Claude Bernard Lyon 1, 69000 Lyon, France. · Service de Chirurgie Gynécologie Obstétrique 2 et Médecine de la Reproduction, CHU Cochin, APHP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Equipe Génomique, Epigénétique et Physiopathologie de la Reproduction, Département Développement, Reproduction, Cancer, Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, 12, rue de l'École de Médecine, 75270 Paris cedex 06, France. · 29 rue de l'Essonne, 91000 Evry, France. · Service de Gynécologie-Obstétrique, CHU Bondy, avenue du 14 Juillet, 93140 Bondy, France; Centre médical du Château, 22, rue Louis-Besquel, 94300 Vincennes, France. · 98 route de Blagnac, 31200 Toulouse, France. · Service de Gynécologie-Obstétrique et Médecine de la reproduction, CHU Tenon, APHP, 4, rue de la Chine, 75020 Paris, France; GRC-6 Centre Expert en Endométriose (C3E), Sorbonne Université, 75005 Paris, France; UMR-S938 INSERM Sorbonne Université, 75005 Paris, France. · Service de Gynécologie-Obstétrique et Reproduction Humaine, CHU Estaing, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France. · 3 rue Pablo Picasso, 92160 Antony, France. · Service d'Assistance médicale à la procréation et de préservation de la fertilité, Hôpital Jeanne de Flandre, CHRU Lille, 1, rue Eugène-Avinée, 59037 Lille cedex, France; EA 4308 Gamétogenèse et qualité du gamète, CHRU Lille, 59037 Lille cedex, France. · EndoFrance, BP 50053, 01124 Montluel cedex, France. · Clinique gynécologique et obstétricale, CHU de Lyon HCL - GH Nord-Hôpital de la Croix Rousse, CHU de Lyon - HCL, 103, Grande Rue de la Croix-Rousse, 69317 Lyon cedex, France. · Service de Gynécologie-Obstétrique, CHI Poissy-St-Germain, 10, rue du ChampGaillard, 78303 Poissy, France; EA 7285 Risques cliniques et sécurité en santé des femmes, Université Versailles - Saint-Quentin-en-Yvelines, 78180 Saint-Quentin-en-Yvelines, France. · Service de Gynécologie-Obstétrique, CHU Bicêtre, APHP, 78, avenue du Général de Gaulle, 94275 Le Kremlin-Bicêtre, France; CESP-INSERM, U1018, Equipe Epidémiologie et évaluation des stratégies de prise en charge: VIH, reproduction, pédiatrie, Université Paris Sud, 94807 Villejuif, France. · Service de Gynécologie-Obstétrique, Hôpital Mère-Enfant, CHU Limoges, 8, avenue Dominique Larrey, 87042 Limoges, France; UMR-1248, Faculté de Médecine, 87042 Limoges, France. · Service de Chirurgie Gynécologique et Oncologique - Obstétrique, CHU Lyon Sud, 69495 Pierre-Bénite cedex, France. · Service de Gynécologie-Obstétrique, CHI Poissy-St-Germain, 10, rue du ChampGaillard, 78303 Poissy, France. · Service de Gynécologie-Obstétrique, CHU Angers, 4, rue Larrey, 49033 Angers cedex 01, France; CESP-INSERM, U1018, Equipe 7, Genre, Santé Sexuelle et Reproductive, Université Paris Sud, 94276 Le Kremlin-Bicêtre cedex, France. · Service de Chirurgie digestive, GH Paris Saint-Joseph, 185, rue Raymond-Losserand, 75001 Paris, France. · Service de Gynécologie-Obstétrique et Médecine de la reproduction, CHU Tenon, APHP, 4, rue de la Chine, 75020 Paris, France; Université Pierre-et-Marie-Curie Paris 6, 75005 Paris, France; GRC6-UPMC: centre expert en endométriose (C3E), hôpital Tenon, Paris, France. · 10 Clinique Tivoli-Ducos, 33000 Bordeaux, France. · Service de Gynécologie-Obstétrique, Centre Hospitalier de Versailles, 177, route de Versailles, 78157 Le Chesnay cedex, France. · Service d'Urologie, CHU Lyon Sud, 165, chemin du Grand Revoyet, 60495 Pierre Bénite, France. · Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital MèreEnfant, CHU Nantes, 8, boulevard Jean-Monnet, 44093 Nantes, France. · Service de Gynécologie-Obstétrique, CH Renée Dubos, 6, avenue de l'Ile-de-France, 95300 Pontoise, France; Université Paris 13, Sorbonne Paris Cité, UFR SMBH, 93022 Bobigny, France. · Centre Expert de Diagnostic et Prise en Charge Multidisciplinaire de l'Endométriose, Clinique Gynécologique et Obstétricale, CHU Charles Nicolle, 1, rue de Germont, 76031 Rouen, France. · Service de Gynécologie-Obstétrique, CHU Bicêtre, APHP, 78, avenue du Général de Gaulle, 94275 Le Kremlin-Bicêtre, France. · Service d'Imagerie, Hôpital Tenon, APHP, 4, rue de la Chine, 75020 Paris, France; Sorbonne Universités, UPMC Univ Paris 06, Institut Universitaire de Cancérologie, Assistance Publique, 75006 Paris, France. · Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Arnaud de Villeneuve, CHU Montpellier, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier, France. · Centre d'étude et traitement de la douleur, Hôpital Claude Huriez, CHRU Lille, rue Michel-Polonowski, 59000 Lille, France. · Service de Gynécologie-Obstétrique, Hôpital Foch, APHP, 40, rue Worth, 92151 Suresnes, France; Centre d'Assistance Médicale à la Procréation, Clinique Pierre Cherest, 5, rue Pierre-Cherest, 92200 Neuilly-Sur-Seine, France. ·J Gynecol Obstet Hum Reprod · Pubmed #29920379.

ABSTRACT: First-line diagnostic investigations for endometriosis are physical examination and pelvic ultrasound. The second-line investigations are: targeted pelvic examination performed by an expert clinician, transvaginal ultrasound performed by an expert physician sonographer (radiologist or gynaecologist), and pelvic MRI. Management of endometriosis is recommended when the disease has a functional impact. Recommended first-line hormonal therapies for the management of endometriosis-related pain are combined hormonal contraceptives (CHCs) or the 52mg levonorgestrel-releasing intrauterine system (IUS). There is no evidence base on which to recommend systematic preoperative hormonal therapy solely to prevent surgical complications or facilitate surgery. After surgery for endometriosis, a CHC or 52mg levonorgestrel-releasing IUS is recommended as first-line treatment when pregnancy is not desired. In the event of failure of the initial treatment, recurrence, or multiorgan involvement, a multidisciplinary team meeting is recommended, involving physicians, surgeons and other professionals. A laparoscopic approach is recommended for surgical treatment of endometriosis. HRT can be offered to postmenopausal women who have undergone surgical treatment for endometriosis. Antigonadotrophic hormonal therapy is not recommended for patients with endometriosis and infertility to increase the chances of spontaneous pregnancy, including postoperatively. Fertility preservation options must be discussed with patients undergoing surgery for ovarian endometriomas.

12 Article [Creation of expert centers on endometriosis]. 2017

Daraï, Emile / Bendifallah, Sofiane / Chabbert-Buffet, Nathalie / Golfier, François. ·Université Pierre et Marie Curie (UPMC), Assistance publique des hôpitaux de Paris, hôpital Tenon, service de gynécologie-obstétrique et reproduction humaine, 4, rue de La Chine, 75020 Paris 6, France; Hôpital Tenon, centre expert en endométriose (C3E), groupe de recherche clinique (GRC-6 UMPC), 75020 Paris, France; UMRS-938, Paris 6, 75012, Paris, France; Hôpital Tenon, centre de diagnostic en un jour de l'endométriose (CDJE), 75020 Paris, France. Electronic address: emile.darai@aehe.fr. · Université Pierre et Marie Curie (UPMC), Assistance publique des hôpitaux de Paris, hôpital Tenon, service de gynécologie-obstétrique et reproduction humaine, 4, rue de La Chine, 75020 Paris 6, France; Hôpital Tenon, centre expert en endométriose (C3E), groupe de recherche clinique (GRC-6 UMPC), 75020 Paris, France. · Université Pierre et Marie Curie (UPMC), Assistance publique des hôpitaux de Paris, hôpital Tenon, service de gynécologie-obstétrique et reproduction humaine, 4, rue de La Chine, 75020 Paris 6, France; Hôpital Tenon, centre expert en endométriose (C3E), groupe de recherche clinique (GRC-6 UMPC), 75020 Paris, France; UMRS-938, Paris 6, 75012, Paris, France; Hôpital Tenon, centre de diagnostic en un jour de l'endométriose (CDJE), 75020 Paris, France. · CHU de Lyon, service de gynécologie-obstétrique, 69000 Lyon, France. ·Presse Med · Pubmed #29169709.

ABSTRACT: Endometriosis is a frequent pathology with a high incidence of deep infiltrating endometriosis and complex forms that can affect 20% of patients with endometriosis. The incidence of infertility associated with endometriosis can reach 50%. The complexity of care requires the creation of expert centers working in networks with general practitioners. Criteria for defining these expert centers are being drawn up, based on structural criteria (multidisciplinary consultation meeting), links with medical assistance structures for procreation and activity criteria for severe and complex forms (number of interventions per center and per surgeon).

13 Article [Fertility and deep infiltrating endometriosis]. 2017

Cohen, Jonathan / Mathieu d'Argent, Emmanuelle / Selleret, Lise / Antoine, Jean-Marie / Chabbert-Buffet, Nathalie / Bendifallah, Sofiane / Ballester, Marcos / Darai, Emile. ·Assistance publique-Hôpitaux de Paris, université Pierre-et-Marie-Curie Paris 6, hôpital Tenon, GRC6-UPMC : centre expert en endométriose (C3E), service de gynécologie-obstétrique et médecine de la reproduction, 75020 Paris, France. Electronic address: drcohenjonathan@gmail.com. · Assistance publique-Hôpitaux de Paris, université Pierre-et-Marie-Curie Paris 6, hôpital Tenon, GRC6-UPMC : centre expert en endométriose (C3E), service de gynécologie-obstétrique et médecine de la reproduction, 75020 Paris, France. · Assistance publique-Hôpitaux de Paris, université Pierre-et-Marie-Curie Paris 6, hôpital Tenon, GRC6-UPMC : centre expert en endométriose (C3E), service de gynécologie-obstétrique et médecine de la reproduction, 75020 Paris, France; Université Pierre-et-Marie-Curie Paris 6, Inserm, UMR_S938, 75012 Paris, France. ·Presse Med · Pubmed #29129409.

ABSTRACT: Deep infiltrating endometriosis is the most severe form of the disease, defined by infiltration beneath the peritoneum greater than 5mm. It affects several anatomical locations including the bladder, the vesico-uterine cul-de-sac, the torus uterinum, the uterosacral ligament, rectovaginal septum and the colon-rectum. Deep infiltrating endometriosis is associated with infertility. Surgery performed for deep infiltrating endometriosis in the context of pain offers good pregnancy rates either spontaneously or after assisted reproductive technologies. The results are less favorable when digestive tract is involved. IVF performed in the context of deep infiltrating endometriosis allows very satisfactory results and does not entail risks of aggravation of the pathology. There is currently no clear evidence to support either IVF or surgery to manage infertility associated with deep infiltrating endometriosis, but patients should be informed, although a risk of severe complication exists, that surgery is the only way to increase the chances of spontaneous fertility.

14 Article Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist. 2017

Kolanska, K / Cohen, J / Bendifallah, S / Selleret, L / Antoine, J-M / Chabbert-Buffet, N / Darai, E / d'Argent, E-M. ·Department of Gynecology and Obstetrics, Tenon Hospital, Assistance publique-Hôpitaux de Paris, Pierre-et-Marie-Curie University (UMPC)-Paris 6, 75020 Paris, France; UMRS-938, Pierre-et-Marie-Curie University-Paris 6, 75020 Paris, France; Clinical Research Group (GRC-6 UPMC): Centre expert en endométriose (C3E), Tenon Hospital, Pierre-et Marie-Curie-University (UMPC)-Paris 6, Assistance publique-Hôpitaux de Paris, 75020 Paris, France. · Department of Gynecology and Obstetrics, Tenon Hospital, Assistance publique-Hôpitaux de Paris, Pierre-et-Marie-Curie University (UMPC)-Paris 6, 75020 Paris, France; UMRS-938, Pierre-et-Marie-Curie University-Paris 6, 75020 Paris, France; Clinical Research Group (GRC-6 UPMC): Centre expert en endométriose (C3E), Tenon Hospital, Pierre-et Marie-Curie-University (UMPC)-Paris 6, Assistance publique-Hôpitaux de Paris, 75020 Paris, France. Electronic address: drcohenjonathan@gmail.com. · Department of Gynecology and Obstetrics, Tenon Hospital, Assistance publique-Hôpitaux de Paris, Pierre-et-Marie-Curie University (UMPC)-Paris 6, 75020 Paris, France; Clinical Research Group (GRC-6 UPMC): Centre expert en endométriose (C3E), Tenon Hospital, Pierre-et Marie-Curie-University (UMPC)-Paris 6, Assistance publique-Hôpitaux de Paris, 75020 Paris, France. ·J Gynecol Obstet Hum Reprod · Pubmed #28970135.

ABSTRACT: BACKGROUND OR OBJECTIVE: Endometriosis is common in women referred for infertility. In vitro fertilization provides good results but the choice of the best-controlled ovarian hyperstimulation protocol remains a subject of debate. The objective of this retrospective study was to compare pregnancy outcomes in women with endometriosis-associated infertility after COH with a long agonist protocol or a six-week oral contraception-antagonist protocol. MATERIAL AND METHODS: Retrospective analysis of a prospective database identified 284 COH cycles - 165 with GnRH-agonist protocol (GnRH-agonist group) and 119 with GnRH-antagonist protocol (GnRH-antagonist group) - in 218 women, with endometriosis from January 2013 to October 2015. RESULTS: No difference in the epidemiological characteristics was found between the groups. Per started cycle, pregnancy and live-birth rates after fresh embryo transfer were higher with the GnRH-agonist protocol (25% vs. 13%, P=0.02 and 18% vs. 8%, P=0.04, respectively). Considering analysis per cycle with embryo transfer, the pregnancy rate was similar in both groups while the live-birth rate was higher in the GnRH-agonist group (29% vs. 17%, P=0.053 and 22% vs. 10%, P=0.02, respectively). No difference was observed between the groups with freeze-thaw embryo transfer. Subgroup analysis (endometrioma alone, deep infiltrating endometriosis with and without endometrioma, endometriosis with and without adenomyosis) revealed no difference between the groups for either pregnancy or live-birth rates. CONCLUSION: A GnRH-agonist protocol appears to result in higher pregnancy and live-birth rates after fresh embryo transfer in women with endometriosis-associated infertility, suggesting that a GnRH-antagonist protocol might negatively impact endometrial receptivity.

15 Article [Deep infiltrative endometriosis without digestive involvement, what is the impact of surgery on in vitro fertilization outcomes? A retrospective study]. 2017

Mounsambote, L / Cohen, J / Bendifallah, S / d'Argent, E Mathieu / Selleret, L / Chabbert-Buffet, N / Ballester, M / Antoine, J M / Daraï, E. ·Department of Obstetrics, Gynecology and Reproductive Medicine, hôpital Tenon, GRC 6-UPMC centre expert en endométriose (C3E), université Pierre-et-Marie-Curie-Paris 6, Assistance publique-Hôpitaux de Paris, 75020 Paris, France. · Department of Obstetrics, Gynecology and Reproductive Medicine, hôpital Tenon, GRC 6-UPMC centre expert en endométriose (C3E), université Pierre-et-Marie-Curie-Paris 6, Assistance publique-Hôpitaux de Paris, 75020 Paris, France; Inserm UMRS 938, université Pierre-et-Marie-Curie, 75012 Paris, France. Electronic address: drcohenjonathan@gmail.com. · Department of Obstetrics, Gynecology and Reproductive Medicine, hôpital Tenon, GRC 6-UPMC centre expert en endométriose (C3E), université Pierre-et-Marie-Curie-Paris 6, Assistance publique-Hôpitaux de Paris, 75020 Paris, France; Inserm UMRS 938, université Pierre-et-Marie-Curie, 75012 Paris, France. ·Gynecol Obstet Fertil Senol · Pubmed #28238309.

ABSTRACT: OBJECTIVES: To evaluate the impact of complete removal of endometriosis in case of deep infiltrative endometriosis without digestive involvement, on in vitro fertilization outcomes. METHODS: Retrospective monocentric study. We included infertile women with deep infiltrative endometriosis without colorectal involvement that underwent IVF. Women were divided in two groups, following their history: "surgery" when they underwent complete endometriosis resection before IVF and "without surgery" when they underwent IVF without endometriosis removal. We analysed IVF outcomes considering pregnancy rates per cycle and cumulative pregnancy rates per patient. RESULTS: We included 72 patients: 35 in the "surgery" group and 37 in the "without surgery" group. Women in the two groups were comparable in terms of baseline characteristics (age, body mass index, anti-Müllerian hormone, antral follicular count), endometriosis localizations and in vitro fertilization parameters. Cumulative pregnancy rates per patient were similar in both groups (40 % in the "surgery" group and 41 % in the "without surgery" group; P=1). Clinical pregnancy rate per cycle were also comparable groups (24 % in the "surgery" group and 28 % in the "without surgery" group; P=0.67). Surgery performed was comparable in women that became pregnant and in women that did not. Age was lower in women that became pregnant (P=0.01) and there were more pregnancy obtained in women under 35 years. CONCLUSION: In women with deep infiltrative endometriosis without digestive involvement, in vitro fertilization outcomes were not impacted by surgery. Therapeutic choice between IVF or surgery as first-line treatment remains thus questionable and shall be guided by other influencing factors, such as pain symptomatology, age, tubal permeability, ovarian reserve, partner's sperm characteristics and woman's choice.

16 Article Effect of induced peritoneal endometriosis on oocyte and embryo quality in a mouse model. 2015

Cohen, J / Ziyyat, A / Naoura, I / Chabbert-Buffet, N / Aractingi, S / Darai, E / Lefevre, B. ·Service de Gynécologie-Obstétrique, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, Université Pierre et Marie Curie Paris 6, GRC 6-UPMC Centre Expert en Endométriose (C3E), Paris, France, drcohenjonathan@gmail.com. ·J Assist Reprod Genet · Pubmed #25399065.

ABSTRACT: PURPOSE: To assess the impact of peritoneal endometriosis on oocyte and embryo quality in a mouse model. METHODS: Peritoneal endometriosis was surgically induced in 33 B6CBA/F1 female mice (endometriosis group, N = 17) and sham-operated were used as control (sham group, N = 16). Mice were superovulated 4 weeks after surgery and mated or not, to collect E0.5-embryos or MII-oocytes. Evaluation of oocyte and zygote quality was done by immunofluorescence under spinning disk confocal microscopy. RESULTS: Endometriosis-like lesions were observed in all mice of endometriosis group. In both groups, a similar mean number of MII oocytes per mouse was observed in non-mated mice (30.2 vs 32.6), with a lower proportion of normal oocytes in the endometriosis group (61 vs 83 %, p < 0.0001). Abnormalities were incomplete extrusion or division of the first polar body and spindle abnormalities. The mean number of zygotes per mouse was lower in the endometriosis group (21 vs 35.5, p = 0.02) without difference in embryo quality. CONCLUSIONS: Our results support that induced peritoneal endometriosis in a mouse model is associated with a decrease in oocyte quality and embryo number. This experimental model allows further studies to understand mechanisms of endometriosis-associated infertility.